Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Today: Quarterly Focus on GU | Bladder Cancer

Quarterly Focus on Genitourinary Cancer: Highlights in Bladder Cancer

In each Quarterly Focus MEDtalks Oncology brings you the unique opportunity to gain more insight into two pivotal publications on Genitourinary Cancer. In the third episode (watch episode 1 on prostate cancer and episode 2 on renal cell carcinoma on-demand) two international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. During the live broadcast on Tuesday November 6th 8.30-9.30 PM CEST you have the possibility to interact with our expert panel and the authors and ask them your questions.

The expert panel consist of:

  • Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam

  • Prof. Fred Witjes, MD, PhD, urologist, Radboudumc, Nijmegen

  • Sjoukje Oosting, MD, PhD, medical oncologist, UMCG, Groningen

Program:

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Lancet 391, 2018

Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391, 2017

Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam

Sign up for this live program

  • Invited speakers

  • Michiel van der Heijden, MD

    medical oncologist

    NKI-AvL, Amsterdam

  • Sjoukje Oosting, MD

    medical oncologist

    UMCG, Groningen

  • Prof. Fred Witjes, MD

    urologist

    Radboudumc, Nijmegen

  • Prof. Dipen Parekh, MD

    medical oncologist

    University of Miami Health System, Miami

  • This program is editorially independent and is financially made possible by

Related items

Congresnieuws 12/03/2015

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congresnieuws 12/09/2017

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.

Congresnieuws 18/02/2017

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congresnieuws 18/02/2017

ASCO-GU 2017: TEE during neoadjuvant chemotherapy for UCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Syed Hussain Poster: B339 - Thrombo-embolic events (TEE) during neoadjuvant chemotherapy for muscle invasive bladder cance

Congresnieuws 18/02/2017

​ASCO GU 2017: Atezolizumab in mUCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Daniel Petrylak Poster: B290 - Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study

Congresnieuws 18/02/2017

​ASCO GU 2017: Durvalumab in advanced UCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Thomas Powles Poster: B286 - Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Congresnieuws 18/02/2017

ASCO GU 2017: KEYNOTE-052

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Arjun Balar Poster: B284 - Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

Congresnieuws 18/02/2017

ASCO GU 2017: Adjuvant radiotherapy after cystectomy

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Abhishek Solanki Poster: B369 - Adjuvant radiotherapy use after radical cystectomy in muscle-invasive bladder cancer: A survey of U.S. radiation oncologists.